Copyright
©The Author(s) 2015.
World J Gastroenterol. Jan 7, 2015; 21(1): 301-310
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.301
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.301
Table 1 Clinical and laboratory data of patients who had reduced steatosis by one degree (n = 22)
| Parameter | Before diet | After diet value | P value | ||
| Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | ||
| Age (yr) | 53.57 ± 13.94 | 60 (20) | 53.57 ± 13.94 | 60 (20) | - |
| Body mass index (kg/m²) | 34.75 ± 6.26 | 33.41(7.2) | 32.22 ± 5.97 | 30.7 (67.21) | NS |
| Aspartatetransaminase (U/L) | 31.86 ± 19.9 | 23 (16) | 28.29 ± 20.86 | 19.5 (3) | NS |
| Alaninetransaminase (U/L) | 57.86 ± 65.6 | 33.5 (27.25) | 39.07 ± 36.28 | 23.5 (15.25) | NS |
| Gammaglutamyltrasferase (U/L) | 50.14 ± 40.2 | 31.5 (39.25) | 40.71 ± 35.25 | 26.5 (25) | NS |
| Triacylglycerols (mg/dL) | 135 ± 3.9 | 115 (41) | 126.79 ± 89 | 106 (33.75) | P < 0.05 |
| Cholesterol (mg/dL) | 206.4 ± 42.45 | 203.5 (41.3) | 195.5 ± 49.3 | 208 (54.2) | NS |
| High density lipoprotein (mg/dL) | 48.21 ± 11.4 | 49.5 (8.5) | 52.07 ± 17.22 | 47.5 (21.5) | NS |
| Low density lipoprotein (mg/dL) | 130.3 ± 42.19 | 129.5 (44.3) | 119 ± 36.5 | 128.5 (46.8) | NS |
| Glucose (mg/mL) | 109.6 ± 51.9 | 96.5 (17.8) | 115.9 ± 65.72 | 101 (14.3) | NS |
| Insulin (U/mL) | 19.6 ± 20.35 | 12.3 (16.48) | 13.1 ± 12.56 | 10.85 (8) | P < 0.055 |
| HOMA-IR | 5.42 ± 6.08 | 2.98 (2.45) | 3.65 ± 3.21 | 2.63 (3.57) | NS |
- Citation: Maciejewska D, Drozd A, Ossowski P, Ryterska K, Jamioł-Milc D, Banaszczak M, Raszeja-Wyszomirska J, Kaczorowska M, Sabinicz A, Stachowska E. Fatty acid changes help to better understand regression of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(1): 301-310
- URL: https://www.wjgnet.com/1007-9327/full/v21/i1/301.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i1.301